Advanced in Basal Cell Skin Cancer

Dr. Todd Schlesinger

Dermatology
Prisma Health
Epiphany Dermatology – Charleston
2180 Henry Tecklenburg Drive, 
Charleston, SC 
On Staff At
Accepting New Patients
Offers Telehealth
Advanced in Basal Cell Skin Cancer
Prisma Health
Epiphany Dermatology – Charleston
2180 Henry Tecklenburg Drive, 
Charleston, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Todd Schlesinger is a Dermatologist in Charleston, South Carolina. Dr. Schlesinger is rated as an Advanced provider by MediFind in the treatment of Basal Cell Skin Cancer. His top areas of expertise are Actinic Keratosis, Acne, Basal Cell Skin Cancer, and Bowen's Disease. Dr. Schlesinger is currently accepting new patients.

His clinical research consists of co-authoring 58 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles in the study of Basal Cell Skin Cancer.

Specialties
Dermatology
Licenses
Dermatology in SC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Epiphany Dermatology – Charleston
2180 Henry Tecklenburg Drive, Charleston, SC 29414
Call: 843-556-8886

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis
Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
Enrollment Status: Terminated
Publish Date: August 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (Spinosad) for the Treatment of Scabies
A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (Spinosad) for the Treatment of Scabies
Enrollment Status: Completed
Publish Date: May 21, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: August 18, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
Azelaic Acid Foam 15% in the Treatment of Papulopustula Rosacea: An Evaluation of Photographic Evidence
Azelaic Acid Foam 15% in the Treatment of Papulopustula Rosacea: An Evaluation of Photographic Evidence
Enrollment Status: Completed
Publish Date: July 24, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 13 Less Clinical Trials

58 Total Publications

Publisher Correction: Risk of Nonmelanoma Skin Cancer in Patients with Moderate-to-Severe Atopic Dermatitis: A United States Population-Based Study.
Publisher Correction: Risk of Nonmelanoma Skin Cancer in Patients with Moderate-to-Severe Atopic Dermatitis: A United States Population-Based Study.
Journal: Dermatology and therapy
Published: November 26, 2025
View All 58 Publications
Similar Doctors
Distinguished in Basal Cell Skin Cancer
Dr. William J. Cook
Dermatology
Distinguished in Basal Cell Skin Cancer
Dr. William J. Cook
Dermatology

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (6.0 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Cook is a Dermatologist in Charleston, South Carolina. Dr. Cook is rated as a Distinguished provider by MediFind in the treatment of Basal Cell Skin Cancer. His top areas of expertise are Squamous Cell Skin Carcinoma, Keloids, Basal Cell Skin Cancer, and Multiple Familial Trichoepithelioma. Dr. Cook is currently accepting new patients.

Distinguished in Basal Cell Skin Cancer
Dr. Anne H. Leclercq
Dermatology
Distinguished in Basal Cell Skin Cancer
Dr. Anne H. Leclercq
Dermatology

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (6.0 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anne Leclercq is a Dermatologist in Charleston, South Carolina. Dr. Leclercq is rated as a Distinguished provider by MediFind in the treatment of Basal Cell Skin Cancer. Her top areas of expertise are Sunburn, Basal Cell Skin Cancer, Hives, and Actinic Keratosis. Dr. Leclercq is currently accepting new patients.

Advanced in Basal Cell Skin Cancer
Dr. David M. Perry
Dermatology
Advanced in Basal Cell Skin Cancer
Dr. David M. Perry
Dermatology

Perry Dermatology And Dermatopathology

48 Folly Rd Blvd, 
Charleston, SC 
 (4.9 miles away)
843-769-2100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Perry is a Dermatologist in Charleston, South Carolina. Dr. Perry is rated as a Distinguished provider by MediFind in the treatment of Basal Cell Skin Cancer. His top areas of expertise are Actinic Keratosis, Syringoma, Eosinophilic Pustular Folliculitis, and Warts. Dr. Perry is currently accepting new patients.

VIEW MORE BASAL CELL SKIN CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schlesinger's expertise for a condition
ConditionClose
  • Elite
  • Actinic Keratosis
    Dr. Schlesinger is
    Elite
    . Learn about Actinic Keratosis.
    See more Actinic Keratosis experts
  • Distinguished
  • Acne
    Dr. Schlesinger is
    Distinguished
    . Learn about Acne.
    See more Acne experts
  • Advanced
  • Atopic Dermatitis
    Dr. Schlesinger is
    Advanced
    . Learn about Atopic Dermatitis.
    See more Atopic Dermatitis experts
  • Basal Cell Skin Cancer
    Dr. Schlesinger is
    Advanced
    . Learn about Basal Cell Skin Cancer.
    See more Basal Cell Skin Cancer experts
  • Bowen's Disease
    Dr. Schlesinger is
    Advanced
    . Learn about Bowen's Disease.
    See more Bowen's Disease experts
  • Lichen Planus
    Dr. Schlesinger is
    Advanced
    . Learn about Lichen Planus.
    See more Lichen Planus experts
  • Lichen Simplex Chronicus
    Dr. Schlesinger is
    Advanced
    . Learn about Lichen Simplex Chronicus.
    See more Lichen Simplex Chronicus experts
  • Lymphocytic Infiltrate of Jessner
    Dr. Schlesinger is
    Advanced
    . Learn about Lymphocytic Infiltrate of Jessner.
    See more Lymphocytic Infiltrate of Jessner experts
View All 8 Advanced Conditions
  • Experienced
  • Cellulitis
    Dr. Schlesinger is
    Experienced
    . Learn about Cellulitis.
    See more Cellulitis experts
  • Cerebral Cavernous Malformation
    Dr. Schlesinger is
    Experienced
    . Learn about Cerebral Cavernous Malformation.
    See more Cerebral Cavernous Malformation experts
  • Cherry Angioma
    Dr. Schlesinger is
    Experienced
    . Learn about Cherry Angioma.
    See more Cherry Angioma experts
  • Contact Dermatitis
    Dr. Schlesinger is
    Experienced
    . Learn about Contact Dermatitis.
    See more Contact Dermatitis experts
  • Eosinophilic Pustular Folliculitis
    Dr. Schlesinger is
    Experienced
    . Learn about Eosinophilic Pustular Folliculitis.
    See more Eosinophilic Pustular Folliculitis experts
  • Epidermodysplasia Verruciformis
    Dr. Schlesinger is
    Experienced
    . Learn about Epidermodysplasia Verruciformis.
    See more Epidermodysplasia Verruciformis experts
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.